Key Points
- Insider sale: Sean Wuxiong Cao sold 107,978 I-Mab shares for approximately $79,904 at an average price of $0.74. The sale, made to cover tax withholding on vested equity awards, reduced his holdings by 28.84% to 266,467 shares.
- Weak financial performance: I-Mab reported a quarterly loss of $0.16 per share, with analysts expecting a full-year loss of $0.30 per share. The stock opened at $1.59, near its one-year low of $1.46, and has a market capitalization of about $183.9 million.
- Mixed analyst sentiment: Ratings range from HC Wainwright’s “buy” recommendation with a $9.00 target to “sell” and “strong sell” ratings from other firms, resulting in a consensus “hold” rating.
I-Mab (NASDAQ:NBP - Get Free Report) insider Sean Wuxiong Cao sold 107,978 shares of the company's stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $0.74, for a total value of $79,903.72. Following the completion of the sale, the insider owned 266,467 shares of the company's stock, valued at $197,185.58. This trade represents a 28.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
I-Mab Stock Performance
Shares of I-Mab stock opened at $1.59 on Friday. I-Mab has a one year low of $1.46 and a one year high of $6.79. The stock's fifty day moving average is $1.81 and its 200 day moving average is $2.13. The stock has a market cap of $183.88 million, a P/E ratio of -4.42 and a beta of 1.50.
I-Mab (NASDAQ:NBP - Get Free Report) last released its quarterly earnings results on Thursday, August 20th. The company reported ($0.16) earnings per share (EPS) for the quarter. Analysts predict that I-Mab will post -0.3 EPS for the current year.
Hedge Funds Weigh In On I-Mab
A hedge fund recently bought a new position in I-Mab stock. Taikang Asset Management Hong Kong Co Ltd bought a new position in shares of I-Mab (NASDAQ:NBP - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 128,765 shares of the company's stock, valued at approximately $512,000. Taikang Asset Management Hong Kong Co Ltd owned approximately 0.11% of I-Mab at the end of the most recent quarter. Hedge funds and other institutional investors own 38.38% of the company's stock.
Analyst Ratings Changes
NBP has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of I-Mab in a research report on Thursday, August 27th. HC Wainwright restated a "buy" rating and set a $9.00 target price on shares of I-Mab in a research note on Thursday, August 20th. Finally, Wall Street Zen downgraded shares of I-Mab from a "sell" rating to a "strong sell" rating in a report on Monday, September 7th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, I-Mab currently has an average rating of "Hold" and a consensus price target of $9.00.
View Our Latest Report on I-Mab
About I-Mab
(
Get Free Report)
I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.
Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
